Introduction
Death-inducing ligands (DILs) are members of the tumor necrosis factor (TNF) family consisting of CD95-L/Fas-L/Apo-1L, TNF-related apoptosis-inducing ligand (TRAIL) and TNFa (Krammer, 2000) . DILs are potent inducers of apoptosis in sensitive target cells, for example, in cancer cells. The apoptosis signal is mediated by specific interaction with their receptors CD95/Fas/Apo-1, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) and TNF-R1, respectively, and involves adapter molecules like FADD. Downstream caspases are activated either directly or by mitochondrial amplification and the apoptosome. Regulatory proteins of intracellular signal transduction include FLIP, members of the Bcl-2 family and IAPs (Scaffidi et al., 1999) . Apoptosis induction by TRAIL mainly depends on both FADD and Caspase-8, and occurs independent of RIP (Krammer, 2000) . Loss of Caspase-8 was shown to cause primary apoptosis -resistance towards TRAIL, for example, in neuroectodermal tumor cells (Teitz et al., 2000) .
Apart from apoptosis, DILs mediate additional signals, for example, proliferation in normal T cells and thymocytes (Budd, 2002) . Nonapoptotic signals by DILs are mediated by intracellular signaling molecules like the mitogen-activated kinases or NF-kB (Herr et al., 1999) . NF-kB is a transcription factor that activates mainly prosurvival genes, for example, cytokines or growth factors involved in proliferation (Karin et al., 2002) , including TRAIL (Baetu et al., 2001) . Activation of NF-kB by DILs antagonizes apoptosis induction and inhibition of NF-kB activation attenuates apoptosis resistance in tumor cells (Jeremias et al., 1998a) . Activation of NF-kB or Jun-kinase by TRAIL is mediated via RIP and occurs independently of Caspase-8 and FADD (Muhlenbeck et al., 1998; Lin et al., 2000) . To further study the effect of TRAIL on tumor cells, we tested primary cells of children with leukemia.
Results and discussion
Antiapoptotic, prosurvival or proliferative effect of TRAIL on apoptosis-resistant primary leukemic cells TRAIL is a promising anticancer drug that induces marked apoptosis in tumor cells of different origin. We tested the in vitro effect of TRAIL on primary cells of 28 children with acute leukemia before the onset of chemotherapy (Table 1) . In line with the published results (Jeremias et al., 1998b) , 50% of the primary blasts showed marked cell death upon incubation with TRAIL up to 70%. In the remaining 50% of samples, leukemic cells were resistant to TRAIL-induced apoptosis. To our surprise, in these apoptosis-resistant samples TRAIL reduced spontaneous apoptosis, for example, from 65 to 55% in patient #22 as measured by forwardside scatter analysis (Table 1) , suggesting an antiapoptotic, prosurvival function of TRAIL. Spontaneous proliferation of a significant fraction of primary cells in vitro is a rare event and was detected in cells of only two patients (#27 and #28). Most importantly and unexpected, in the absence of apoptosis induction TRAIL mediated proliferation in these two primary samples increasing concentration from 2 Â 10 6 cells/ml (100%) to 2.27 Â 10 6 cells/ml (114%) within 48 h in sample #27 (Figure 1a) , which corresponds to a decrease in doubling time from 48 to 38 h. Most impressive, while cells of patient #28 showed little growth under control conditions, TRAIL strongly increased both the number and size of proliferating colonies (sixfold, Figure 1b ,c), reduced spontaneous cell death (Figure 1d ) and increased the percentage of cells in G 2 M phase ( Figure 1e ) and total cell count ( Figure 1f ). As the observed increase in tumor cell count represents a yet unknown and potentially harmful function of TRAIL during anticancer treatment, we studied this prosurvival function of TRAIL in more detail.
TRAIL-mediated proliferation in apoptosis-resistant cell lines
To elucidate the effect of TRAIL on apoptosis-resistant tumor cells, we generated a TRAIL apoptosis-resistant derivative JURKAT cell line (J-TR) by weekly incubation of parental sensitive JURKAT cells (JS) with sublethal doses of TRAIL so that apoptosis induction reached 95% each week. This treatment caused a continuous logarithmic increase in TRAIL resistance up to a 1000-fold (Figure 2a ). Even after 28 weeks of continuous TRAIL treatment, all cells could still be killed by overdoses of TRAIL suggesting a continuous Figure 1 . Percentage of specific apoptosis by TRAIL was calculated as ((apoptosis of TRAIL-treated cellsÀapoptosis of control cells)/(100Àapoptosis of control cells) Â 100). TRAIL-mediated survival was calculated as (survival in TRAIL-treated culture/survival in control culture Â 100). TRAIL-mediated proliferation was measured after 48 h and calculated as (cell count in TRAIL-treated culture (for patient #27 2258 Â 10 3 cells/ml, for patient #28 1200 Â 10 3 cells/ml)/cell count in control culture (for patient #27 1988 Â 10 3 cells/ml, for patient #28 1045 Â 10 3 cells/ml) Â 100) J-TR cells reacted with an even higher increase in tumor cell count upon stimulation with TRAIL of yeast or bacterial origin compared to the primary blasts of patient #27 and #28, augmenting cell number from 100% (spontaneous growth) in average to 113% within just 24 h (Figure 3a , range from 100 to 120% in the presence of TRAIL). For readout of Absolute number of proliferating colonies were 17 in the control culture and 30 in the TRAIL-treated culture. In addition, the number of cells of each colony was counted; mean colony size was 2.2 and 2.6, respectively. One representative out of five independent experiments is shown as the mean of four parallel measurements plus standard error. (e) J-TR cells were seeded at 10 6 cells/ml in PBS to suppress spontaneous proliferation and were incubated at 371C for 8 h. Cell concentration was estimated as in (a). Data are mean of duplicates with a standard deviation of less than 5%, one representative experiment out of three is shown. (f) Caspase-8-negative JURKAT A3 cells (Juo et al., 1998) and control cells were (black bar) or were not (gray bar) incubated with TRAIL for 24 h, cell concentration was estimated and depicted as the mean of five independent experiments as in (a). (g) Neuroectodermal CADO (e) cells were (black bar) or were not (gray bar) incubated with TRAIL for 24 h, BrdU test was performed four times independently, results are depicted as in (c), standard error was o5% TRAIL-induced proliferation in cancer cells H Ehrhardt et al proliferation, manual cell counting and BrdU incorporation showed similar results (Figure 3a-c) . The percentage of cells in the G 2 /M phase showed a slight, but statistically significant increase upon treatment with TRAIL (data not shown). In growing cells, TRAIL did not alter spontaneous cell death (data not shown). In an adapted form of a colony-forming assay, TRAIL treatment lead to both an increased number of proliferating cells as well as an augmented size of colony (Figure 3d ). When J-TR were kept under nonproliferative conditions, TRAIL inhibited spontaneous cell death (Figure 3e ) similar to data obtained in primary cells (Table 1 ).
TRAIL-induced proliferation in cancer cells
Additional cells were tested, which display resistance towards TRAIL-induced apoptosis because of the lack of Caspase-8, such as an additional derivative JURKAT T-cell line (Juo et al., 1998) (Figure 3f ), CEM cells lacking Caspase-8 (data not shown) as well as the neuroectodermal cell lines CADO and Sy5y with absent Caspase-8 expression because of promoter hypermethylation (Fulda and Debatin, 2002) (Figure 3g and data not shown). All cell lines exhibited proliferation by incubation with TRAIL, in average from 100 (spontaneous growth) to 114% within 24 h extending the proliferative effect of TRAIL to nonleukemic cancer cells. All cell lines with apoptosis resistance 
H Ehrhardt et al Figure 5 Essential role of NF-kB for TRAIL-mediated proliferation. (a) JURKAT cells indicated were incubated with TRAIL (TR) or TNFa (300 ng/ml) for 30 min. Total cellular native proteins were analysed by electromobility shift assay using radioactive NF-kB binding oligonucleotide. For test of specificity, unlabeled NF-kB-binding oligonucleotide (co 1) or unspecific unlabeled oligonucleotide (co 2) was added in excess to TNFa treatment (co ¼ control). One representative out of three experiments is shown. (b) Where indicated, J-TR cells were pretreated with Norleu (3 mm) for 24 h followed by TRAIL (TR) for 30 min. EMSA was performed as in (a). One representative out of three independent experiments is shown. (c) J-TR cells were preincubated with Norleu (3 mm) for 24 h, then TRAIL was (black bars) or was not (gray bars) added for 24 h. Cell concentration was estimated and depicted as in Figure 1 (a) . Shown is the mean plus standard error for four independent experiments. (d) Control cells and RIP-negative JURKAT cells (Ting et al., 1996) were (black bar) or were not (gray bar) stimulated with TRAIL for 24 h in the presence of zVAD (20 mm). Cell concentration was estimated as in Figure 1 towards TRAIL tested so far showed additional proliferation by treatment with TRAIL (data not shown). As FADD might signal proliferation (Hueber et al., 2000) , JURKAT cells expressing the dominant-negative form of FADD were included, which also showed TRAILmediated proliferation to 113% within 24 h (data not shown), suggesting that neither Caspase-8 nor FADD are involved in TRAIL-mediated proliferation. Thus, inhibition of apoptosis by disruption of receptor proximal signaling may allow TRAIL-induced survival and proliferation. To see whether TRAIL-mediated proliferation is continuous, culture cells were split down to 250 000 cells/ml every second day. Under these conditions, TRAIL-mediated proliferation could be detected for indefinite time periods (Figure 4a , b, performed for up to 14 days, data not shown) independent of variable spontaneous growth. TRAIL increased proliferation in J-TR cells at different concentrations ranging from 100 000 cells/ml up to 3 Â 10 6 cells/ml (Figure 4c, d) . In J-TR cells, TRAIL augmented cell numbers up to 163% within 4 days as compared to control (100%) and accelerated doubling time from 24 to 19 h (Figure 4c, d) , which corresponds to a doubling in tumor load within 5.5 days by TRAIL. Therefore, the effect of TRAIL on cell growth is exponential and becomes potentiated over time and may have significant clinical implications for the use of TRAIL in tumor therapy.
Essential role of NF-kB for TRAIL-mediated proliferation
Upon binding to its receptors TRAIL-receptor 1 and 2 (DR4 and DR5), TRAIL activates two distinct intracellular pathways, one inducing apoptosis via FADD and activation of caspases and a second one that activates NF-kB via RIP (Lin et al., 2000) . Activation of NF-kB by TRAIL was shown to antagonize apoptosis induction and inhibition of its activation enables apoptosis induction in otherwise TRAIL apoptosis-resistant tumor cells (Jeremias et al., 1998a) . Until now, no direct function of TRAIL-mediated activation of NF-kB is known.
In response to TRAIL, J-TR cells activated NF-kB to a similar extent compared to JS cells as shown by gel shift assay using NF-kB consensus sequence (Figure 5a ). Activation of NF-kB was inhibited by proteasome inhibitor Norleu (Figure 5b ). Proteasome inhibitors used in concentrations where spontaneous growth was not affected, completely abrogated TRAILmediated proliferation in J-TR cells (Figure 5c for Norleu, similar results for Lactacystin, data not shown) and in JURKAT A3 Caspase-8 À/À (data not shown).
To block activation of NF-kB by TRAIL at the molecular level, three derivative JURKAT cell lines were used, one lacking RIP (Ting et al., 1996) , because RIP is essential for the activation of NF-kB by TRAIL (Lin et al., 2000) , one lacking IKKg, because IKKg is necessary for the activation of NF-kB by various stimuli in JURKAT cells (Harhaj et al., 2000) and one overexpressing a dominant-negative form of IkBa (IkBa 2ND4). As all three cell lines are sensitive for TRAIL-induced apoptosis, proliferation assays were performed in the presence of zVAD. In contrast to control cells, RIP-and IKKg-negative JURKAT cells did not exhibit enhanced proliferation upon stimulation with TRAIL (Figure 5d, e) . In addition, JURKAT cells transfected with the super-repressor IkBa 2ND4 did not show increased proliferation upon TRAIL stimulation when the expression of the protein was initiated by doxycyclin (Figure 5f ), suggesting that TRAIL-induced proliferation depends on RIP-mediated activation of NF-kB.
Conclusion
Our data describe for the first time the biological significance of TRAIL-mediated activation of NF-kB in tumor cells resistant towards apoptosis induction by TRAIL: TRAIL enhances survival and/or proliferation.
TRAIL is the first DIL involved in proliferation of cancer cells. TNFa and CD95-L were shown to induce proliferation in various normal cells, for example, in lymphocytes (Budd, 2002) . Activation of the CD95 receptor by agonistic antibodies was rarely shown to induce proliferation in tumor cells (Mapara et al., 1993) , although CD95 seems to react differently in response to agonistic antibodies compared to the natural ligand (Thilenius et al., 1997) .
The following signaling molecules are involved in TRAIL-mediated tumor cell increase: TRAIL-R2 as JURKAT cells express no TRAIL-R1, RIP but not FADD as the essential adapter molecule, which then activates NF-kB.
The TRAIL-mediated net increase in tumor cell count may be caused by different mechanisms: (1) TRAIL prevents cell death of otherwise dying cells; (2) TRAIL induces proliferation in otherwise resting cells and is thus mitogenic; and (3) TRAIL shortens the cycling time in proliferating cells. The coexistence of all three mechanisms was found in cells of patient #28.
In cancer therapy, TRAIL might represent a potential risk for patients with TRAIL apoptosisresistant tumor cells as it might increase tumor growth. Further studies including in vivo animal models of TRAIL apoptosis-resistant tumors are necessary to elaborate the clinical relevance of TRAIL-mediated survival and proliferation of TRAIL apoptosis-resistant tumors.
Materials and methods

Materials
TRAIL (used at 1 mg/ml) was expressed in P. pastoris as described (Jeremias et al., 1998b) . As control, TRAIL produced in E. coli (Alexis Corp., Lausanne, Switzerland and Pepro Tech., Rocky Hill, NJ, USA) was used. Apo-1 was used in the presence of Protein A (5 ng/ml), TNFa (Calbiochem, San Diego, CA, USA) was used in the presence of cycloheximide (100 ng/ml, Sigma). zVAD was obtained by Calbiochem, San Diego, CA, USA. Further agents were obtained by Sigma, Deisenhofen, Germany.
Immunodetection of proteins by Western blot was achieved using the following antibodies: anti a-Tubulin from Oncogene, San Diego, CA, USA; anti-Bid from Trevigen, Gaithersburg, MD, USA; anti-FLIP and anti-Caspase-9 from Pharmingen, San Diego, CA, USA; anti-XIAP from Transduction, Lexington, KY, USA; anti-PARP from Roche, Basel, Switzerland; anti-Caspase-10 from MBL International, Watertown, MA, USA; and anti-NFkBp65 from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Anti-Caspase-8 mAb was a kind gift by M Peter.
Cell culture
Cell lines were maintained in RPMI 1640 (GIBCO, Life Technologies, Karlsruhe, Germany) supplemented with 10% FCS (Seromed, Berlin, Germany). Caspase-8-negative Jurkat A3 cells and control cells were a kind gift by John Blenis (Juo et al., 1998) , RIP-negative cells and parental JURKAT SVT35 cells were a kind gift by Brian Seed (Ting et al., 1996) . IKKg-negative cells and parental JURKAT cells were a kind gift by Shao-Cong Sun (Harhaj et al., 2000) .
Primary leukemic blasts were obtained from 28 children treated for acute leukemia at the Ludwig Maximilians University's childrens' hospitals during 2000 and 2001. Samples were obtained by bone marrow puncture at initial diagnosis or diagnosis of relapse, isolated using Ficoll-Isopaque (Amersham, Uppsala, Sweden), and examined by forwardside scatter analysis in FACscan after 24 h in culture.
Apoptosis assays
Cells were seeded at 1 Â 10 6 /ml. After 24 h, apoptosis was measured by forwardside scatter analysis in FACscan (Becton Dickinson, Heidelberg, Germany). For mitochondrial membrane potential, cells were stained with DiOC 6 (Sigma) for 15 min at 371C and measured in fluorescence-1 in FACscan.
Cell count assays
Cells were seeded at concentrations of 0.1-1 Â 10 6 /ml. After 2-6 h of rest, TRAIL was added every 24 h. Cell concentration was estimated using Neugebauer chamber and counting Trypan blue excluding cells in a blinded way so that the examiner did not know the cells' treatment. BrdU test was performed according to the manufacturer's instructions (Roche, Basel, Switzerland) using 24 h incubation time for BrdU. All experiments were performed eightfold in parallel. For the measurement of cell cycle, cells were lysed at the end of the experiment and stained with propidium iodide to measure DNA length (Nicoletti et al., 1991) . To obtain nonproliferating conditions, J-TR cells were seeded at 10 6 cells/ml in PBS for 8 h.
Colony-forming assay J-TR cells were seeded at 500 cells/ml in Methocult H4433 (Cell Systems, Katharinen, Germany) supplemented with 10% FCS for up to 48 h as TRAIL could not be added repeatedly. In patients, colonies were counted under routine cell culture conditions per 100 ml in a 96-well plate.
Western blot analysis, electromobility gel shift assay
Western blot analysis was performed as described (Jeremias et al., 1998b) . EMSA was performed as described (Kupatt et al., 1999) .
Statistical analysis
Whenever possible, one-way repeated measure analysis of variance (RM ANOVA) was used. Student-Newman-Keuls ttests were applied to isolate statistical differences whenever a difference was detected by ANOVA. Otherwise t-test was applied, P-values o0.05 were used to test for statistical significance.
